7427 Stock Overview
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Great Novel Therapeutics Biotech & Medicals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$61.00 |
| 52 Week High | NT$110.50 |
| 52 Week Low | NT$44.55 |
| Beta | 0.081 |
| 1 Month Change | 28.42% |
| 3 Month Change | 6.64% |
| 1 Year Change | -33.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -6.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7427 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 7.0% | -1.1% | -0.6% |
| 1Y | -33.8% | -21.5% | 29.2% |
Return vs Industry: 7427 underperformed the TW Biotechs industry which returned -21.5% over the past year.
Return vs Market: 7427 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 7427 volatility | |
|---|---|
| 7427 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 7427's share price has been volatile over the past 3 months.
Volatility Over Time: 7427's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 12 | Chia-Nan Chen | www.gntbm.com.tw |
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation.
Great Novel Therapeutics Biotech & Medicals Fundamentals Summary
| 7427 fundamental statistics | |
|---|---|
| Market cap | NT$2.35b |
| Earnings (TTM) | -NT$61.54m |
| Revenue (TTM) | NT$4.85m |
484.1x
P/S Ratio-38.1x
P/E RatioIs 7427 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7427 income statement (TTM) | |
|---|---|
| Revenue | NT$4.85m |
| Cost of Revenue | NT$2.24m |
| Gross Profit | NT$2.62m |
| Other Expenses | NT$64.16m |
| Earnings | -NT$61.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 53.92% |
| Net Profit Margin | -1,268.87% |
| Debt/Equity Ratio | 0% |
How did 7427 perform over the long term?
See historical performance and comparison